Coronary/Structural Heart

Caristo diagnostics logo

Caristo’s CaRi-Heart® FAI-Score™ Demonstrates Superior Prognostic Capability in Landmark Study of 19,110 Patients Published in JAMA Cardiology

Very high coronary inflammation assessment in patients with a calcium score of zero associated with a 14.1x higher risk of cardiovascular death Very high coronary inflammation assessment without calcified or non-calcified plaque associated with a 10.4x higher risk of cardiovascular death…

Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen LIONHEART-HCM oHCM Phase 3 enrolling with interim analysis expected in second half of 2027; TRUEHEART-HCM fixed-dose oHCM Phase 2b and NOBLEHEART-HCM Phase 3 in nHCM on track to initiate in first half of 2027 Cash, cash equivalents and investments of $503.5 million; cash runway expected into 2029 SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) — Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases, today reported unaudited financial results for the third quarter ended September 30, 2026, and provided a business update. “BHB-1893 continues to show a consistent, potentially differentiated profile across multiple clinical studies and our mechanistic work,” said Travis Murdoch, M.D., President and Chief Executive Officer of Braveheart Bio. “The 52-week data presented at AHA showed rapid, deep responses that continued to improve over time, including meaningful improvements in pVO2 and KCCQ-CSS, and evidence supporting a highly simplified dosing regimen. These results inform our updated development strategy, including TRUEHEART-HCM, which will evaluate a fixed dose in oHCM on top of standard of care. With LIONHEART-HCM enrolling, NOBLEHEART-HCM on track to initiate in the first half of 2027 and a strong balance sheet, we are focused on delivering a potential best-in-disease profile with a simple dosing paradigm for patients with HCM.” Recent Business Highlights AHA Scientific Sessions 2026 Clinical Data Presentations 52-Week Open-Label Extension in Obstructive HCM (“oHCM”): Braveheart Bio and partner Hengrui Pharma presented 52-week open-label extension (“OLE”) data from the Phase 2 study of BHB-1893 in 42 patients with oHCM in a late-breaking oral presentation. Mean peak oxygen uptake (“pVO2”) and Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (“KCCQ-CSS”) improved by 2.7 mL/kg/min and 17.3 points, respectively, from OLE baseline. By Week 1, before any titration, 67% of patients achieved a Valsalva left ventricular outflow tract gradient (“LVOT-G”) below 30 mmHg; 90% reached this threshold at one or more visits during 52 weeks of treatment. At Week 52, 57% of patients remained on the 40 mg twice-daily starting dose. In an exploratory analysis, gradient and NT-proBNP levels after washout were lower following 52 weeks of treatment than following 12 weeks, consistent with potential reverse remodeling. BHB-1893 was generally well tolerated, with no on-treatment severe or serious adverse events.New data supporting differentiated mechanism of action: Braveheart Bio presented preclinical mechanistic data from engineered heart tissue models and an ad hoc pooled analysis of the Phase 2 study of BHB-1893 in non-obstructive HCM (“nHCM”). BHB-1893 improved indices of diastolic function while preserving systolic performance, both in vitro and in patients; at Week 12, a majority of BHB-1893-treated patients had normal septal and lateral e′ velocities (59% and 57%, respectively, compared with 14% and 18% of placebo-treated patients). 52-week data from the nHCM Phase 2 OLE are expected in the first half of 2027. Development Strategy Update On November 6, 2026, Braveheart Bio hosted an investor event, “HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor,” featuring leading HCM experts, and outlined its updated clinical development strategy for BHB-1893, which is designed to minimize titration while optimizing efficacy. A replay is available in the Investors section of Braveheart Bio’s website.LIONHEART-HCM, Global Phase 3 Trial in oHCM: LIONHEART-HCM is enrolling patients. It is a global, randomized, double-blind, active-comparator-controlled Phase 3 trial evaluating the efficacy and safety of BHB-1893 compared to metoprolol in patients with symptomatic oHCM, using a 40 mg twice-daily starting dose with a single potential titration step to 60 mg at Week 4. The primary endpoint is change in pVO2 from baseline to Week 24; secondary endpoints include LVOT gradient, NT-proBNP and KCCQ-CSS. Results from an interim analysis of LVOT gradient at Week 12 are expected in the second half of 2027.Hengrui Pharma’s Study 301, a Phase 3 Trial in oHCM in China: Hengrui Pharma, Braveheart Bio’s collaboration partner in Greater China, has completed enrollment in its Phase 3 trial of HRS-1893 on top of standard of care, with topline results expected in the first half of 2027.NOBLEHEART-HCM, Global Phase 3 Trial in nHCM: Braveheart Bio has completed its end-of-Phase 2 meeting with the FDA and plans to initiate NOBLEHEART-HCM in the first half of 2027. NOBLEHEART-HCM is a planned global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating BHB-1893 in adults with symptomatic nHCM. The trial design includes a potential single titration step at Week 4. The dual primary endpoints are change in pVO2 and KCCQ-CSS from baseline to Week 36.TRUEHEART-HCM, Phase 2b Fixed-Dose Trial in oHCM: TRUEHEART-HCM is a planned Phase 2b trial evaluating a fixed 40 mg twice-daily dose of BHB-1893, with no titration visits, on top of standard of care in patients with symptomatic oHCM. Braveheart Bio has received supportive FDA feedback on the fixed-dose approach and is finalizing the protocol to enable trial initiation in the U.S. in the first half of 2027.Braveheart Bio completed its upsized initial public offering in August 2026, selling 24,437,500 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares, at $18.00 per share for gross proceeds of approximately $439.9 million. Braveheart Bio’s common stock began trading on the Nasdaq Global Market under the ticker symbol “BRVE” on August 6, 2026. Third Quarter 2026 Financial Results Cash, cash equivalents and investments were $503.5 million as of September 30, 2026, compared to $89.2 million as of December 31, 2025. Based on the current operating plan, Braveheart Bio estimates that its existing cash, cash equivalents and investments will be sufficient to fund its projected operating expenses and capital expenditure requirements into 2029. Research and development (R&D) expenses were $17.5 million for the three months ended September 30, 2026, compared to less than $0.1 million for the same period in 2025. The increase was primarily due to clinical and manufacturing costs to support the initiation and enrollment of LIONHEART-HCM, higher personnel-related costs and a $1.0 million milestone under the Hengrui license agreement. There was no in-process research and development (“IPR&D”) expense for the three months ended September 30, 2026, compared to $58.8 million for the same period in 2025, which related to the in-license of BHB-1893 from Hengrui. General and administrative (G&A) expenses were $12.6 million for the three months ended September 30, 2026, compared to $0.5 million for the same period in 2025. The increase was primarily due to personnel-related costs, including stock-based compensation, and consultant and legal costs to support Braveheart Bio’s growth and operations as a public company. G&A expenses for the three months ended September 30, 2026 included $7.8 million of non-cash stock-based compensation expense, of which $6.1 million related to liability-classified modified executive restricted stock awards that are remeasured to fair value each reporting period. Net loss was $26.5 million, or $0.51 net loss per share, basic and diluted, for the three months ended September 30, 2026, compared to a net loss of $59.1 million, or $10.05 net loss per share, basic and diluted, for the same period in 2025. Braveheart Bio, Inc.Selected Condensed Statements of Operations Data (Unaudited)(in thousands, except share and per share data)  Three Months Ended September 30,Nine Months Ended September 30,  2026  2025  2026  2025 Operating expenses:    Research and development$17,542 $9 $39,581 $9 In-process research and development –  58,770  –  59,218 General and administrative 12,607  508  21,499  540 Total operating expenses 30,149  59,287  61,080  59,767 Loss from operations (30,149) (59,287) (61,080) (59,767)Total other income 3,654  169  5,317  169 Net loss$ (26,495)$ (59,118)$ (55,763)$ (59,598)Deemed dividends upon issuance of redeemable convertible preferred stock –  –  (3,615) – Net loss attributable to common stockholders$(26,495)$(59,118)$(59,378)$(59,598)Net loss per share, basic and diluted$(0.51)$(10.05)$(2.66)$(20.46)Weighted-average shares of common stock outstanding, basic and diluted 52,095,078  5,881,011  22,285,633  2,912,682  Selected Condensed Balance Sheet Data (Unaudited)(in thousands)  September 30, 2026December 31, 2025Cash, cash equivalents and investments$503,520$89,161 Total assets 514,450 89,350 Total liabilities 16,848 5,333 Redeemable convertible preferred stock – 149,889 Total stockholders’ equity (deficit) 497,602 (65,872) About Braveheart Bio Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. For more information, please visit http://www.braveheart.bio. Forward-Looking Statements This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the clinical development of BHB-1893 and other product candidates, including the initiation, timing, progress, results and future data releases of ongoing and planned clinical trials; the timing of enrollment, progress and expected results from the LIONHEART-HCM global Phase 3 trial; the potential for data from Hengrui’s Phase 3 trial of BHB-1893 in oHCM, together with the LIONHEART-HCM interim analysis, to support a New Drug Application submission; the timing of topline results from Hengrui’s Phase 3 trial and of 52-week data from the Phase 2 nHCM open-label extension; the timing of initiation as well as expected results from the NOBLEHEART-HCM global Phase 3 trial in nHCM; the timing of initiation, progress and expected results from the TRUEHEART-HCM Phase 2b fixed-dose study; Braveheart Bio’s interactions and communications with regulatory authorities and timing as well as anticipated results of submissions; the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of Braveheart Bio’s product candidates; its ability to develop and advance its potential future product candidates and programs; and expectations for Braveheart Bio’s uses of capital, expenses and financial results, including its cash runway into 2029. Any forward-looking statements in this press release are based on Braveheart Bio’s current expectations and assumptions. These statements are neither promises nor guarantees and involve risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, risks relating to: Braveheart Bio’s research and development activities; Braveheart Bio’s ability to obtain the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to clinical development activities; Braveheart Bio’s reliance on clinical data generated by Hengrui and on Hengrui for the manufacture of BHB-1893; Braveheart Bio’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Braveheart Bio’s ability to attract, integrate and retain key personnel; risks related to Braveheart Bio’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Braveheart Bio’s intellectual property protections; risks related to geopolitical developments and U.S. and Chinese laws and regulations, including the BIOSECURE Act; and risks related to the competitive landscape for Braveheart Bio’s product candidates; as well as the other risks and uncertainties described under the heading “Risk Factors” section in Braveheart Bio’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and any subsequent filings Braveheart Bio makes with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date of this press release. Except as required by applicable law, Braveheart Bio undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Braveheart Bio intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Braveheart Bio’s Investor Relations website, in addition to following Braveheart Bio’s press releases, SEC filings, public conference calls, presentations, and webcasts. Investor Relations ContactAlexander SharifNew Street Investor RelationsAlexander@NewStreetIR.com Media ContactFGS GlobalBraveheart-bio@fgsglobal.com

JenaValve Presents Late-Breaking JENA-VAD Data at TCT 2026, Demonstrating High Technical Success and 30 Day Safety of the Trilogy System in LVAD Patients Under IDE

– Data reflects outcomes from 50 patients with Left Ventricular Assist Devices (LVADs) and Clinically Significant Aortic Regurgitation (AR) treated with the Trilogy System- Demonstrated 96% technical success with no deaths or strokes, at 30 days in a patient population with significant comorbidities and limited options- Data simultaneously published in the Journal of the American College of Cardiology (JACC)- Additionally, the Company successfully presented a live Trilogy case from Cedars-Sinai IRVINE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy Transcatheter Heart Valve (THV) System, today announced highlights from the 2026 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in San Diego, CA. JenaValve presented late-breaking data from the JENA-VAD Registry investigational study in the US, a prospective, multicenter registry evaluating the Trilogy System in patients with an LVAD and clinically significant AR. Early outcomes were shown from fifty patients, demonstrating high technical success with no adverse events or serious complications and early improvements in functional status and patient-reported quality of life. Dr. Torsten Vahl, director of translational research and interventional cardiologist at NewYork-Presbyterian/Columbia University Irving Medical Center presented the results of the JENA-VAD Registry, which were simultaneously published in the Journal of the American College of Cardiology (JACC), linked here. AR has historically been reported in up to 20% to 30% of patients within two to three years of continuous-flow LVAD support. In these patients, AR creates a recirculation loop between the pump and the left ventricle, which reduces systemic flow and leads to congestion and recurrent heart failure. Surgical options carry high risk in this population. Transcatheter valves designed for aortic stenosis often anchor poorly in the noncalcified anatomy typical of AR, which can lead to migration or the need for a second valve. The Trilogy System instead uses locators that clip the native aortic leaflets, so it does not depend on annular calcification to anchor. “Many patients with LVADs develop aortic regurgitation, yet treatment options remain extremely limited, considering the very high risk of surgery. The continuous mechanical support provided by the LVAD, combined with the absence of leaflet calcification, creates a particularly high risk of valve embolization with TAVR devices developed for aortic stenosis,” said Dr. Vahl. “In the JENA-VAD Registry, the Trilogy valve was successfully implanted in 50 patients with LVADs, with no instances of valve migration, embolization or need for a second valve. We observed high rates of technical and device success without any deaths or strokes within 30 days, and no significant paravalvular leak. These results are exceptionally encouraging and demonstrate the feasibility of the Trilogy valve in this particularly challenging patient population. We are excited that this technology may finally offer a meaningful treatment option for patients with LVADs who develop aortic regurgitation.” Fifty patients were treated in the JENA-VAD Registry at 14 U.S. centers. All patients were NYHA class III or IV at baseline, and all had undergone prior open-heart surgery. Technical success and 30-day device success were each 96.0%. Ninety percent of patients were free from the VARC-3 early safety composite at 30 days. There were no deaths or strokes within 30 days and no moderate or greater prosthetic regurgitation. No patient had valve migration or needed a second valve. Early findings also point to improvements in symptoms: at 30 days, 72.3% of patients assessed had mild or no heart failure symptoms (NYHA class I or II), compared with none before the procedure. JENA-VAD is being conducted under an investigational device exemption (IDE) and is nested within the ALIGN-AR trial. “Historically, patients with an LVAD who develop AR have had very few good options, and the functional improvements we saw in JENA-VAD are highly encouraging,” said Ravi Ramana, DO, Heart Care Centers of Illinois and national principal investigator of the prospective JENA-VAD Registry. “It remains early, but we look forward to continuing to follow these patients. The thrombosis findings and open questions about anticoagulation in this population call for systematic imaging and longer follow-up, and the one-year results will be essential.” “The JENA-VAD Registry reflects our commitment to evaluating the Trilogy System rigorously in patients with few alternatives and to reporting what we learn transparently,” said Gabriel Sayer, MD, Associate Director of Advanced Heart Failure, Cardiac Transplantation and Mechanical Circulatory support at New York-Presbyterian and national principal investigator of the JENA-VAD Registry. “These results provide promising data in a very high-risk population and we look forward to continued follow up and further research to better define what this device may mean for LVAD patients with AR in the future.” An additional highlight of TCT 2026 was a live case broadcast from Cedars-Sinai Medical Center in Los Angeles, featuring the successful implantation of the Trilogy transcatheter heart valve in a patient with severe aortic regurgitation. The procedure was performed by Raj Makkar, MD, of Cedars-Sinai Medical Center, providing attendees with a real-time demonstration of the Trilogy system in clinical practice. About JenaValveJenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative THV solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy THV System is a TAVR system designed to treat patients with symptomatic, severe AR, and symptomatic, severe aortic stenosis (AS) who are at high surgical risk. The Trilogy THV System has regulatory approvals in the United States and Europe for its intended use, and reflects JenaValve’s focus on addressing unmet clinical needs in aortic valve disease, including aortic regurgitation. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, United Kingdom, and Munich, Germany. JenaValve is backed by Bain Capital Life Sciences, Andera Partners, Valiance Life Sciences, Rosetta Capital, Cormorant Asset Management, Legend Capital, NeoMed Management, RMM, VI Partners, Pictet Alternative Advisors SA, Qatar Investment Authority (QIA), Innovatus Capital Partners, and Peijia Medical Limited. Additional information is available at www.jenavalve.com. JenaValve Contact:Daniel Sun dsun@jenavalve.com Investor Contacts:Marissa BychGilmartin Group LLCmarissa@gilmartinir.com

Amgen logo v2

NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM

Independent VESALIUS-CV Analysis Finds Repatha Highly Cost-Effective in High-Risk Patients Without a Prior Heart Attack or Stroke Long-Term FOURIER External-Control Analysis Shows Repatha Associated With 29% Lower Risk of Major Cardiovascular Events in Patients Living With ASCVD THOUSAND…

Pivotal Study Validates Cordio Medical’s Smartphone-Based Voice Analysis for Remote Heart Failure Monitoring

Results Presented as Late-Breaking Science at the American Heart Association (AHA) Scientific Sessions 2026 Blinded, Multicenter Study of 563 Patients Identified Risk 24.6 Days in Advance and Saw 85% Compliance and High Patient Satisfaction CHICAGO, Nov. 9, 2026 /PRNewswire/ — Cordio…

New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy

— In a randomized crossover study, sotagliflozin significantly reduced ex vivo thrombus formation from baseline under both arterial and venous flow conditions — — Study in living human heart tissue indicate sotagliflozin acutely and directly reduces myocardial work in hypertrophic cardiomyopathy (HCM) — — Findings add mechanistic insight into sotagliflozin’s dual SGLT1/SGLT2 inhibition ahead of SONATA-HCM topline results in Q1 2027 — THE WOODLANDS, Texas, Nov. 09, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced new data highlighting the cardiovascular effects of its dual SGLT1/2 inhibitor, sotagliflozin, which were shared in two poster presentations at the American Heart Association (AHA) Scientific Sessions 2026. The investigator-initiated studies were sponsored by Lexicon and conducted by investigators at the Ichan School of Medicine at Mount Sinai and Penn Cardiovascular Institute. In the first presentation, “Zafar et al. Effects of Sotagliflozin and Empagliflozin on Thrombus Formation in Healthy Volunteers: A Randomized Crossover Trial”, researchers from the Ichan School of Medicine examined whether sotagliflozin reduces the blood’s tendency to form clots, which are the leading cause of heart attacks and strokes. In the 4-week, randomized, open-label crossover study, 15 healthy adults received once-daily sotagliflozin 400 mg and the selective SGLT2 inhibitor empagliflozin 10 mg in random order. Researchers measured clot formation in participants’ blood before and after each treatment, using an ex vivo laboratory model in which blood is drawn over a system that mimics a damaged artery and at speeds that replicate arterial and venous blood flow. Sotagliflozin significantly reduced clot formation from baseline under both arterial-like (11.9%; p=0.043) and venous-like (15.6%; p=0.012) conditions. Reductions with empagliflozin did not reach statistical significance. The second presentation, “Taichman et al. Load-Dependent Effects of Sodium Glucose Co-Transporter Inhibitors on Work in Human Hypertrophic Cardiomyopathy Living Myocardial Slices,” examined whether sotagliflozin acts directly on human heart muscle affected by HCM. Researchers at Penn Cardiovascular Institute used heart tissue removed from patients with HCM during septal myectomy, a surgery to relieve obstruction, along with tissue from non-failing donor hearts. In an ex vivo model using living myocardial slices, myocardial work was studied across a physiologic range of afterloads, or the pressures the heart pumps against. Short-term exposure to sotagliflozin and empagliflozin directly reduced the work performed by the heart muscle. Sotagliflozin showed increased potency versus empagliflozin at higher afterloads, which mimics the HCM condition. The findings indicate that sotagliflozin can act directly on the heart, independent of its effects on the kidneys and metabolism. The findings were simultaneously published in JACC: Basic to Translational Science. “A growing body of research continues to suggest that adding SGLT1 inhibition may contribute to cardiovascular effects beyond those seen with SGLT2 inhibition alone,” said Craig Granowitz, M.D., Ph.D., senior vice president and chief medical officer of Lexicon. “The thrombosis data point to a potential mechanism behind the reductions in heart attack and stroke seen in SCORED, while the human tissue findings show a direct effect of sotagliflozin on the hypercontractile heart muscle that characterizes HCM. Together, these new datasets strengthen the scientific rationale for sotagliflozin in HCM and reinforce our excitement for the pivotal readout of our SONATA-HCM study.” The ongoing Phase 3 SONATA-HCM trial is evaluating sotagliflozin as a potential treatment option for patients with symptomatic obstructive and non-obstructive HCM. Topline results are expected in the first quarter of 2027. About Sotagliflozin Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract and the heart. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients. Sotagliflozin is also currently under investigation for hypertrophic cardiomyopathy (HCM). About Lexicon Pharmaceuticals Lexicon Pharmaceuticals is a biopharmaceutical company pursuing novel medicines for patients with serious cardiometabolic diseases. Building on a proven legacy in genetic target discovery, Lexicon is advancing a clinical pipeline in areas of significant and often underserved need, with programs in hypertrophic cardiomyopathy (HCM), type 1 diabetes (T1D), obesity and other related metabolic conditions. Lexicon is committed to developing differentiated therapies that can be integrated broadly into clinical practice, with the goal of expanding treatment options for patients. Its capabilities extend from early-stage target discovery through clinical development and commercialization, strategically paired with high-impact collaborations to maximize the global reach of its medicines. For additional information, please visit www.lexpharma.com. Safe Harbor Statement This press release contains “forward-looking statements,” including statements relating to the research, development and therapeutic and commercial potential of sotagliflozin, including in hypertrophic cardiomyopathy. In addition, this press release may also contain forward-looking statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. For Media Inquiries: Dave Belian Lexicon Pharmaceuticals, Inc. lexinvest@lexpharma.com For Investor Inquiries: Lisa DeFrancesco Lexicon Pharmaceuticals, Inc. lexinvest@lexpharma.com

Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026

– Humacyte has initiated the CABG clinical study and looks forward to the commencement of screening for potential patients.  – “Moving it into a first-in-human study is the step that will tell us whether an off-the-shelf conduit can perform in the coronary position,” says cardiothoracic surgeon Alan Kypson, M.D. DURHAM, N.C., Nov. 09, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced that it has initiated the Phase 2a study of its investigational coronary tissue engineered vessel (CTEV) in patients undergoing coronary artery bypass grafting (CABG). The CTEV and the Company’s regenerative medicine platform were highlighted in three presentations at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, Illinois. The AHA Scientific Sessions is one of the world’s largest gatherings of cardiovascular clinicians and scientists. On Saturday, November 7, John H. Alexander, M.D., M.H.S., Professor of Medicine/Cardiology, Duke Clinical Research Institute at Duke University and Alan Kypson, M.D., Cardiothoracic Surgeon at UNC Rex Hospital, presented the design of the Phase 2a study in “First-in-Human Phase 2a Study Design of a Bioengineered Human Coronary Artery for Coronary Artery Bypass Grafting.” The FDA accepted Humacyte’s Investigational New Drug (IND) application in July 2026, and the study will evaluate the safety and efficacy of the CTEV as a vascular conduit in ten adult patients with coronary artery disease. Patency will be assessed two months after implant, and patients will be followed for up to three years. The study is now open for enrollment. “Every cardiac surgeon has faced the patient who needs a bypass, but doesn’t have usable vein, and our options in those cases are limited,” said Dr. Kypson. “I have worked with this vessel in large-animal models for years and moving it into a first-in-human study is the step that will tell us whether an off-the-shelf conduit can perform in the coronary position.” More than 400,000 coronary arterial grafts are placed each year in the United States. The current conduits used for CABG are autologous vessels harvested from the patient, most often the saphenous vein in the leg. However, saphenous vein graft patency at one year is often as low as 75%, and harvesting the vein can cause surgical wound complications such as infection, and some patients do not have adequate vein available. The CTEV is a small-diameter bioengineered vessel designed as an off-the-shelf conduit for CABG and is produced using the same manufacturing system as Humacyte’s FDA-approved acellular tissue engineered vessel (ATEV). On Saturday, November 7, Dr. Niklason delivered an invited talk, “Engineering the Microenvironment to Accelerate Vascular Regeneration,” in a special session on bioengineering human tissue for congenital heart disease, describing how Humacyte’s acellular engineered vessels are designed to be repopulated by a patient’s own cells after implantation, and may serve as materials to form biological heart valves that could grow with the pediatric patient. “The Phase 2a CABG study marks the first time our bioengineered vessel technology will be evaluated in coronary bypass surgery, and it builds on years of preclinical work in multiple large-animal models,” said Dr. Niklason. “Our goal with the CTEV is to give cardiac surgeons an off-the-shelf conduit that can repopulate with a patient’s own cells, without the need to harvest a vein from the leg or an artery from the arm.” On Sunday, November 8, Robert Kirkton, Ph.D., Executive Director of New Product and Process Development at Humacyte, presented results from porcine and ovine CABG models in “Evaluation of Tissue Engineered Human Vessels in Porcine and Ovine Models of Coronary Artery Bypass Grafting.” These results included successful implantation of ~12 cm-long CTEV bypasses for up to three months in sheep demonstrating patency and host recellularization of the CTEV wall with smooth muscle cells as well as luminal endothelial cells along the length of the CTEV CABG conduit. This work builds on a previous preclinical CABG study in baboons, published in JACC: Basic to Translational Science, in which the CTEV maintained mechanical integrity and conduit patency for up to six months while becoming recellularized with host vascular smooth muscle and endothelial cells. The CTEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency. About Humacyte Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com. For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency. Forward-Looking Statements This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended March 31, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Humacyte Investor Contact:Joyce AllaireLifeSci Advisors LLC+1-617-435-6602jallaire@lifesciadvisors.cominvestors@humacyte.com Humacyte Media Contact:Rich LuchettePrecision Strategies+1-202-845-3924rich@precisionstrategies.commedia@humacyte.com

Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

– In the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat demonstrated sustained reduction in automated office systolic blood pressure (AOSBP) of 17.8 mmHg at Week 48 from Launch-HTN baseline – – 56% of participants reached AOSBP below 130 mmHg at Week 48 – – Long-term treatment with lorundrostat was well tolerated, with no new clinically relevant safety findings beyond Launch-HTN – – U.S. FDA review of lorundrostat is underway, with a PDUFA target date of December 22, 2026 – RADNOR, Pa., Nov. 08, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced long-term results from the Transform-HTN open-label extension trial of lorundrostat in participants with uncontrolled or resistant hypertension, demonstrating sustained reductions in AOSBP following lorundrostat treatment in Launch-HTN. The results were presented in a late-breaking oral session at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, IL, on Sunday, November 8, 2026, at 3:35 p.m. CT. “For patients whose blood pressure remains uncontrolled despite multiple medications, particularly those in high-risk populations disproportionately affected by hypertension, the question in practice is whether a treatment can deliver both rapid and sustained blood pressure control,” said Manish Saxena, MBBS, Clinical Co-Director of Queen Mary University of London’s William Harvey Clinical Research Centre and Hypertension Specialist at Barts Health NHS Trust. “In Transform-HTN, lorundrostat demonstrated sustained blood pressure reductions for nearly a year, with more than half of participants achieving the guideline-recommended systolic blood pressure target of less than 130 mmHg, an important goal for reducing long-term cardiovascular and kidney risks.” Efficacy Results from Transform-HTN In this open-label extension trial, lorundrostat demonstrated a clinically meaningful 17.8 mmHg absolute reduction in AOSBP from the Launch-HTN baseline through 48 weeks (p

PARAMOUNT, the First Randomized Trial of AI-Enabled Plaque-Based Care, Meets Primary Endpoint in Late-Breaking Results at AHA 2026

DENVER–(BUSINESS WIRE)– #AI–Cleerly, a leader in advanced cardiovascular imaging analysis, today presented primary results from PARAMOUNT, the first randomized trial of AI-QCT-guided care against usual care, as Late-Breaking Science at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. Compared with usual care based on stress testing, care guided by AI-based quantitative coronary CT analysis (AI-QCT) improved diagnostic certainty and led to more patients receiving lipid-lowe

Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026

HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52 weeks Data support a highly simplified dosing regimen, with a majority of patients potentially served by the starting dose HRS/BHB-1893 data across both forms of hypertrophic cardiomyopathy (HCM) and preclinical models suggest potential to address underlying pathophysiology of disease, findings consistent with reverse-remodeling and diastolic benefits Braveheart Bio to host Investor Event and Webcast today at 3:35 p.m. CT (4:35 p.m. ET), including discussion of a planned fixed-dose oHCM study, TRUEHEART-HCM SHANGHAI and SAN FRANCISCO, Nov. 06, 2026 (GLOBE NEWSWIRE) — Hengrui Pharma (SSE: 600276; HKEX: 1276) and Braveheart Bio (NASDAQ: BRVE) today presented data from a 52-week open-label extension (OLE) of the Phase 2 study of the investigational, next-generation cardiac myosin inhibitor HRS/BHB-1893 in patients with obstructive hypertrophic cardiomyopathy (oHCM). The data were presented at the American Heart Association (AHA) Scientific Sessions 2026. After the 12-week core period and a washout period, all 42 patients restarted HRS/BHB-1893 for an additional 52 weeks in the OLE. At Week 52, peak oxygen uptake (pVO2) increased by a mean of 2.7 mL/kg/min from OLE baseline; Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) increased by a mean of 17.3 points over the same period. At Week 52, 79% (33/42) of patients achieved a Valsalva LVOT gradient (LVOT-G) below 30 mmHg, with 90% of patients achieving a Valsalva gradient